Please ensure Javascript is enabled for purposes of website accessibility

Is Novavax Stock Still a Buy With Its Management's Credibility Crumbling?

By Keith Speights – Aug 9, 2021 at 5:59AM

Key Points

  • Last week, Novavax pushed back its anticipating U.S. EUA filing for its COVID-19 vaccine from Q3 to Q4.
  • The company's management has established a pattern of setting timelines that they couldn't deliver on.
  • However, Novavax should still ultimately win EUAs in multiple countries and generate billions of dollars in sales.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's executives have repeatedly overpromised and underdelivered.

There are lots of mistakes that corporate executives can make. One of the most problematic is overpromising and underdelivering. This blunder can lead to an erosion of credibility. Novavax (NVAX -2.88%) CEO Stan Erck and his leadership team face this very issue right now.

The company has maintained for a while now that it planned to file for U.S. Emergency Use Authorization (EUA) of its COVID-19 vaccine candidate NVX-CoV2373 in the third quarter of 2021. However, Novavax announced last Thursday in its second-quarter update that its EUA submission in the U.S. will be pushed back into Q4.

The vaccine stock sank on Friday following the news. Is Novavax still a buy with its management's credibility crumbling?

Speech bubble containing the word "delayed" with a blue background.

Image source: Getty Images.

Delay after delay

One case of overpromising and underdelivering usually isn't a cause for serious concern. Unfortunately, Novavax's executives have now established a pattern.

In February, Erck stated that the company expected to file for U.S. EUA of its COVID-19 vaccine candidate in the early second quarter and that it could be available in the U.S. by May. His timing assumed that the U.S. Food and Drug Administration (FDA) would accept a submission based on U.K. clinical study data.

However, Erck acknowledged that the FDA might require Novavax to use its U.S. clinical study data for an EUA filing. He said on March 1, 2021, that in this scenario a U.S. submission could be pushed back to mid-summer. 

By May, Novavax had revised its forecast. The company stated in its Q1 update that a U.S. EUA filing was expected in the third quarter. Investors continued to look for a Q3 submission until the latest delay announced last week. 

Still some uncertainty

Erck said in Novavax's Q2 conference call that he believes "all of the key components are in place to achieve our filing within the fourth quarter." However, the company still must complete the validation of its analytical methods as well as working with third parties to finalize its EUA submission. 

The involvement of third parties is important for Novavax. It's a small company with no previous FDA regulatory filings under its belt. Using other organizations to bolster its limited resources makes sense. However, the use of third parties also increases the risk of further delays.

Other statements that Erck made underscore that there is still some uncertainty. In reference to the U.S. EUA filing, he said, uncertainly, "The current timeline looks to now be in the fourth quarter, hopefully early in the fourth quarter." 

Novavax still expects to file for U.K. EUA in the third quarter. However, Erck added that "as with all applications, this may change." 

Buy, but don't buy

It's totally understandable if investors find it hard to place much trust in Novavax's projected timelines. A pattern of overpromising and underdelivering has taken an inevitable toll on management's credibility. Despite this disappointing track record, though, I still think Novavax's shares could and likely will move significantly higher. 

Last week, Novavax announced a deal with the European Commission to supply up to 200 million doses of its COVID-19 vaccine. The company also has a supply deal with Canada for 52 million doses plus an option for up to 24 million additional doses. It finalized an agreement with the COVAX Facility for 1.1 billion doses. Novavax's partner, SK Bioscience, will supply 40 million doses of NVX-CoV2373 to South Korea. 

The bottom line is that Novavax could have billions of dollars flowing into its coffers once its COVID-19 vaccine wins EUAs and approvals around the world. And while its submission in the U.S. has been pushed back, the company (in collaboration with the Serum Institute of India) has already filed for EUA in India, Indonesia, and the Philippines.

My view is that Novavax remains on track to win EUA in multiple countries, including the United States. The clinical data supporting NVX-CoV2373 hasn't changed.

After its sell-off on Friday, Novavax's market cap is below $15 billion. Considering its realistic revenue prospects in 2022 and beyond, that's a low valuation. I think buying Novavax stock still makes sense, even if buying what its management team might promise doesn't.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax Stock Quote
$16.54 (-2.88%) $0.49

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.